Editas Medicine (EDIT) Enterprise Value (QoQ) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.47% |
| Sep 30, 2025 | 7.20% |
| Jun 30, 2025 | 19.22% |
| Mar 31, 2025 | 18.14% |
| Dec 31, 2024 | -1.82% |
| Sep 30, 2024 | 5.02% |
| Jun 30, 2024 | 5.76% |
| Mar 31, 2024 | 8.34% |
| Dec 31, 2023 | 7.58% |
| Sep 30, 2023 | 19.06% |
| Jun 30, 2023 | -35.65% |
| Mar 31, 2023 | 7.50% |
| Dec 31, 2022 | 17.96% |
| Sep 30, 2022 | 7.28% |
| Jun 30, 2022 | 7.33% |
| Mar 31, 2022 | 2.30% |
| Dec 31, 2021 | 10.40% |
| Sep 30, 2021 | 8.63% |
| Jun 30, 2021 | 2.36% |
| Mar 31, 2021 | -55.51% |
| Dec 31, 2020 | 18.82% |
| Sep 30, 2020 | 17.27% |
| Jun 30, 2020 | -44.27% |
| Mar 31, 2020 | 9.22% |
| Dec 31, 2019 | -37.44% |
| Sep 30, 2019 | -4.62% |
| Jun 30, 2019 | 7.06% |
| Mar 31, 2019 | 7.29% |
| Dec 31, 2018 | -9.32% |
| Sep 30, 2018 | 1.91% |
| Jun 30, 2018 | 4.11% |
| Mar 31, 2018 | -9.02% |
| Dec 31, 2017 | -11.31% |
| Sep 30, 2017 | 8.96% |
| Jun 30, 2017 | 7.61% |
| Mar 31, 2017 | -89.70% |
| Dec 31, 2016 | 7.28% |
| Sep 30, 2016 | 8.17% |
| Jun 30, 2016 | 5.04% |
| Mar 31, 2016 | -172.37% |
| Dec 31, 2015 | 45.81% |
| Sep 30, 2015 | -230.15% |
| Jun 30, 2015 | -810.57% |